RT Journal Article
T1 Long acting injectables & implants: advances in intraocular drug delivery
A1 Cuello Rodríguez, Selene
A1 Blanco Fernández, Guillermo
A1 García Otero, Xurxo
A1 Díaz Tomé, Victoria
A1 Otero Espinar, Francisco Javier
A1 Seoane Viaño, Iria
K1 Intraocular drug delivery systems
K1 PLGA
K1 Intravitreal polymeric and lipid-based implants
K1 Microparticles and nanoparticles
K1 Controlled-release drug delivery platfforms
K1 Intravitreal hydrogels
K1 Age-related macular degeneration
AB The treatment of posterior segment ocular diseases, such as age-related macular degeneration and diabetic retinopathy, poses a significant challenge for ophthalmologists due to the eye’s complex anatomy and physiological barriers. To overcome these challenges, intravitreal drug delivery offers a promising solution by enabling direct administration of therapeutic agents into the pathological area through an injection. However, these injections are highly invasive and carry several risks, including infection, retinal detachment, and increased intraocular pressure. As a result, considerable efforts have been directed toward developing drug delivery platforms (implants, nano- and microparticles, and hydrogels) capable of providing sustained drug release over extended periods. These long-acting systems aim to reduce the frequency of injections, thereby improving patient quality of life and decreasing the overall economic burden of treatment. This review provides an overview of intravitreal drug delivery systems, evaluating their clinical applicability and the potential challenges that must be addressed before they can be successfully translated into marketed drug products.
PB Elsevier
SN 0378-5173
YR 2025
FD 2025-08-09
LK https://hdl.handle.net/10347/43843
UL https://hdl.handle.net/10347/43843
LA eng
NO Cuello-Rodríguez, S., Blanco-Fernández, G., García-Otero, X., Díaz-Tome, V., Otero-Espinar, F. J., & Seoane-Viaño, I. (2025). Long acting injectables & implants: advances in intraocular drug delivery. International Journal of Pharmaceutics, 683, 126058. 10.1016/j.ijpharm.2025.126058
NO This work was partially supported by Ministry of Science and Innovation of Spain (MICINN) [PID2022-142350OB-C21], and Xunta de Galicia [Grupo de Referencia Competitiva, ED431C 2021/26]. I.S.-V., V. D.-T. and X.G.-O. acknowledge Consellería de Cultura, Educaci´on e Universidade for their Postdoctoral Fellowships (Xunta de Galicia, Spain; ED481D-2024-011, ED481B-2023-092, and ED481B-2023-063, respectively).
DS Minerva
RD 29 abr 2026